Newsroom

Sorted by: Latest
-

Indie Thriller Series BirdDog to Premiere at Cinemark Tinseltown Las Palmas on February 24, 2026

EL PASO, Texas--(BUSINESS WIRE)--ReDiscover Television, a 100GROUP client, and CLO Prods proudly announce the world premiere of BirdDog, a gripping new indie drama-thriller series created and written by Christine Lozano. Filmed entirely in the vibrant border city of El Paso, Texas, BirdDog stars Jessica Jimenez, Nichole Hamilton, Talia Leilani, Adam Zarowski, Russell Elleby and Xavier Felix as a ragtag crew of FBI rejects recruited into BirdDog Unit under CISA, Cybersecurity and Infrastructure...
-

ARDT ALERT: Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Ardent Health, Inc. Investors

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired Ardent Health, Inc. (“Ardent” or the “Company”) (NYSE:ARDT) securities during the period of July 18, 2024 through November 12, 2025, inclusive (“the Class Period”). If you suffered a loss on your Ardent investments, you have until March 9, 2026 to request lead plaintiff appointment. For more information: [CONTACT THE FIRM IF YOU SUFFERED A LOSS]...
-

FRMI Investors Have Opportunity to Lead Fermi Inc. Securities Fraud Lawsuit with the Schall Law Firm

LOS ANGELES--(BUSINESS WIRE)--FRMI Investors Have Opportunity to Lead Fermi Inc. Securities Fraud Lawsuit with the Schall Law Firm...
-

SKYE Deadline: Rosen Law Firm Urges Skye Bioscience, Inc. (NASDAQ: SKYE) Stockholders to Contact the Firm for Information About Their Rights

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Skye Bioscience, Inc. (NASDAQ: SKYE) between November 4, 2024 and October 3, 2025. Skye is a clinical stage biopharmaceutical company. For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. The Allegations: Rosen Law Firm is Investigating the Allegations that Skye Bioscience, Inc. (NASDAQ: SKYE) Misled Investors Regarding its Business Ope...
-

FLY Deadline in 3 Days: Kessler Topaz Meltzer & Check, LLP Reminds Firefly Aerospace Inc. (FLY) Investors of Filing Deadline in Class Action Lawsuit

RADNOR, Pa.--(BUSINESS WIRE)--The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that a securities class action lawsuit has been filed against Firefly Aerospace Inc. (“Firefly”) (NASDAQ: FLY) on behalf of those who purchased or otherwise acquired Firefly: (1) common stock pursuant and/or traceable to the registration statement and related prospectus (collectively, the “Offering Documents”) issued in connection with the company’s IPO conducted on or about August 7, 2025; an...
-

Riassunto: Biocytogen e Acepodia ampliano la collaborazione attraverso uno schema di valutazione basato sulle opzioni per ADC bispecifici e con doppio payload (BsAD2C) primi nella categoria

PECHINO, ALAMEDA, Calif. e TAIPEI, Taiwan--(BUSINESS WIRE)--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) e Acepodia (6976:TT), oggi hanno annunciato la firma di un accordo di opzione e licenza finalizzato a permettere la valutazione strutturata di programmi coniugati farmaco-anticorpo bispecifico (BsADC) per promuovere ulteriormente lo sviluppo di coniugati farmaco-anticorpo bispecifico con doppio payload (BsAD2Cs). L'accordo accorda ad Acepodia un'opzio...
-

Biocytogen et Acepodia élargissent leur collaboration grâce à un cadre d'évaluation basé sur les options des ADC bispécifiques à double charge utile (BsAD2C) de première génération

BEIJING et ALAMEDA, Californie et TAIPEI, Taiwan--(BUSINESS WIRE)--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE : 688796 ; HKEX : 02315) et Acepodia (6976 : TT) ont annoncé aujourd'hui que les entreprises ont conclu un accord d'option et de licence destiné à permettre l'évaluation structurée des programmes de conjugués anticorps-médicament bispécifiques (BsADC) afin de faire progresser le développement de conjugués anticorps-médicament bispécifiques à double charge utile (BsA...
-

Resumen: Biocytogen y Acepodia firman un contrato de opción para fortalecer el desarrollo conjunto de innovadores ADC biespecíficos y de carga dual (BsAD2C)

PEKÍN y ALAMEDA, California, y TAIPÉI, Taiwán--(BUSINESS WIRE)--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) y Acepodia (6976:TT) anunciaron hoy la firma de un contrato de opción y licencia con el objetivo de establecer un marco para la evaluación estructurada de programas de conjugados anticuerpo-fármaco biespecíficos (BsADC) y seguir avanzando en el desarrollo de conjugados anticuerpo-fármaco biespecíficos de carga dual (BsAD2C). El acuerdo otorga a Ac...
-

Samenvatting: Biocytogen en Acepodia breiden samenwerking uit door middel van een op opties gebaseerd evaluatiekader voor eersteklas bispecifieke en dual-payload ADC's (BsAD2C)

BEIJING & ALAMEDA, Calif. & TAIPEI, Taiwan--(BUSINESS WIRE)--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) en Acepodia (6976:TT) hebben vandaag bekendgemaakt dat zij een optie- en licentieovereenkomst hebben gesloten om een gestructureerde evaluatie van bispecifieke antilichaam-geneesmiddelconjugaatprogramma's (BsADC) mogelijk te maken. Hiermee beogen ze de ontwikkeling van bispecifieke antilichaam-geneesmiddelconjugaten met dubbele lading (BsAD2C's) verd...
-

Biocytogen und Acepodia erweitern Kooperation durch optionsbasiertes Evaluierungsmodell für bispezifische und Dual-Payload-First-in-Class-ADC (BsAD2C)

PEKING, China, ALAMEDA, Kalifornien, USA, und TAIPEH, Taiwan--(BUSINESS WIRE)--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) und Acepodia (6976:TT) haben heute den Abschluss einer Options- und Lizenzvereinbarung bekannt gegeben, die eine strukturierte Evaluierung von Programmen für bispezifische Antikörper-Wirkstoff-Konjugate (BsADC) vorsieht, um die Entwicklung von bispezifischen Antikörper-Wirkstoff-Konjugaten mit doppelter Wirkstoffladung (BsAD2Cs) vor...